News | March 21, 2026
Bristol Myers Squibb scores major win with new Opdivo nods for Hodgkin Lymphoma in US, EU
These approvals represent a defining moment for people living with classical Hodgkin Lymphoma
These approvals represent a defining moment for people living with classical Hodgkin Lymphoma
Pfizer recommends that shareholders do not tender their shares in response to Tutanota’s offer
The trial met its primary endpoint, with the combination therapy demonstrating a “statistically significant and clinically meaningful” improvement in radiographic progression-free survival
The partnership is designed to close the gap between classroom learning and real-world pharmaceutical practice
The study hit its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in radiographic progression-free survival (rPFS) compared to placebo plus XTANDI
The kit features ViaPlex 405 Barcoding Dye for the 405 nm laser/Pacific Blue filter and ViaPlex 488 Barcoding Dye for the 488 nm laser/FITC filter
The study included four independent genetic substudies targeting obesity caused by heterozygous variants in the POMC/PCSK1, LEPR, SRC1 (NCOA1), and SH2B1 genes
The move aims to accelerate drug discovery with AI-driven designs powered by NVIDIA technology
RSM01, a preventive treatment targeting respiratory syncytial virus (RSV), was licensed earlier this month from the Gates Medical Research Institute
The move opens Japan’s advanced life science market to Epigenica’s high-throughput epigenetic profiling kits
Subscribe To Our Newsletter & Stay Updated
